A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers
A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers
The purpose of this study is to evaluate the dose-proportionality of the pharmacokinetics of
 tapentadol (CG5503) in healthy Japanese and Korean adult male participants.
This is a single-dose, open-label, single-center, randomized, four-way crossover study, ie,
 participants and investigator know the identity of the drug, which is assigned by chance,
 like flipping a coin, and participants may receive different interventions sequentially
 during the study. The study will consist of 4 treatment periods. A single dose of tapentadol
 (CG5503) will be administered orally with 240 mL of water under fasted conditions. All
 participants will receive 1 of the following 4 oral treatments in each period.

 Treatment A: One 25-mg tablet (25 mg) of tapentadol (CG5503) Treatment B: One 50-mg tablet
 (50 mg) of tapentadol (CG5503) Treatment C: One 100-mg tablet (100 mg) of tapentadol (CG5503)
 Treatment D: Two 100-mg tablets (200 mg) of tapentadol (CG5503) Each period will be separated
 by 7 - 14 days.
Inclusion Criteria:

 -  Healthy Japanese and Korean male volunteers, inclusive

 -  Body mass index (BMI) between 18.5 and 25 kg/m², inclusive, and a body weight of not
 less than 50 kg

 -  Japanese volunteers must have resided outside of Japan for no more than 5 years, and
 their parents and maternal and paternal grandparents are Japanese.

 -  Korean volunteers must have resided outside of Korea for no more than 5 years and
 their parents and maternal and paternal grandparents are Korean.

 Exclusion Criteria:

 -  History of or current clinically significant medical illness including (but not
 limited to) cardiac arrhythmias or other cardiac disease

 -  History of hematologic disease, coagulation disorders (including any abnormal bleeding
 or blood dyscrasias), lipid abnormalities

 -  History of significant pulmonary disease, including bronchospastic respiratory disease

 -  History of diabetes mellitus, renal or hepatic insufficiency, thyroid disease,
 neurologic or psychiatric disease, infection, or any other illness that the
 investigator considers should exclude the participant or that could interfere with the
 interpretation of the study results

 -  Use of any prescription or nonprescription medication (including vitamins and herbal
 supplements), except for paracetamol-acetaminophen, within 14 days before the first
 dose of the study drug is scheduled

 -  History of, or a reason to believe a participant has a history of drug or alcohol
 abuse within the past 5 years